The effect of low-dose okt3 monoclonal-antibody therapy on k562 cytotoxicity in human cancer-patients.
Low concentrations of monoclonal antibodies (mAb) specific for the CD3 component of the T cell receptor complex (TcR) may be both immunosuppressive or potent activators of T cell function in vitro depending upon the experimental situation. The anti-CD3 mAb OKT3 is imnmunosuppressive at high doses (5 mg/day for 10 to 14 days) in transplant patients. We undertook a preliminary study to investigate the effect of a single intravenous injection of 50 mu g to 0.5 mu g of OKT3 mAb in cancer patients. OKT3 modulated cytotoxicity with minimal clinical toxicity at low doses and may be of use in cancer immunotherapy protocols.